ArticleBMC complementary medicine and therapies2025
Breaking the silence: factors influencing complementary therapy disclosure among diabetic outpatients in Taiwan.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundAs more patients turn to complementary therapies (CTs) alongside conventional medicine, the lack of communication between patients who use CTs and their conventional healthcare professionals (HCPs) can pose significant risks, including the potential for serious drug interactions. PURPOSE: To explore the factors influencing the disclosure of CTs use to conventional HCPs.
methodsA cross-sectional survey design was employed to enroll 307 outpatients diagnosed with diabetes from both the northern and southern regions of Taiwan, covering the period from October 2022 to March 2023. The survey questionnaire included demographics, the patterns of CTs use, the experiences of CTs use, the Understanding the Benefit-Risks of CTs Use Scale, and the Diabetes Empowerment Scale. The data were analyzed using IBM SPSS Statistics version 28.0.
resultsOnly one-third of outpatients with diabetes disclosed their use of CTs to conventional HCPs. Several factors emerged as influential in this disclosure: understanding the benefits and risks of CTs use (OR = 1.10), the reasons for initial CTs use (OR = 1.58), integration of both conventional and complementary medicines (OR = 15.03), and the use of manipulative-based therapies (OR = 6.82).
conclusionUnderstanding the factors that influence the disclosure of CTs use is essential for conventional HCPs. This understanding allows them to identify outpatients who may hesitate to disclose their CTs use and ensures they have a comprehensive understanding of their patients' CTs use, thereby facilitating effective communication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.